BDRX
$0.79
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain.
Recent News
European Equities Traded in the US as American Depositary Receipts Higher Monday
European equities traded in the US as American depositary receipts were rising on Monday morning, up
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late